InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, held its 16th Annual Internal Scientific Meeting. The Meeting combined a warm and welcoming atmosphere with insightful discussions on key priorities and future opportunities, strengthening the team's strong engagement and collaborative spirit.
Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, opened the Meeting by the overview of InSysBio’s recent achievements, projects and organizational changes. Through collaborations with leading pharmaceutical companies and cutting-edge biotech innovators in 2025, InSysBio has advanced the application of QSP modeling to support drug development and decision-making. InSysBio focused on such therapeutic areas as oncology, immune-oncology, immunology & inflammation, neurodegenerative diseases and rare diseases.
The meeting featured a review of InSysBio's 2025 performance, during which team members highlighted their key contributions to ongoing projects. The presentations concluded with an engaging discussion on the company's future outlook, strategic priorities, and opportunities for continued growth.
Moreover, InSysBio’s own fully-fledged QSP infrastructure that includes QSP softs (Heta, Likelihood Profiler), databases (CYTOCON DB, fIVE DB) and Cloud infrastructure for multiple simulations were significantly enhanced throughout the year and further update is underway. In 2025 InSysBio presented its QSP modeling services and software to optimize drug development at AACR, PAGE, JuliaCon Paris, BioTechX Europe, and ACoP.
Looking ahead, InSysBio remains focused on sustainable development and innovation. This year InSysBio has already presented its results at AGAH Conference, QSPC, ChinaBio and is going to participate in SITC and ACoP 2026.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
| ||
Thank you for your message! We will get back to you shortly.
